a novel t-cell protein which recognizes a palindromic sequence in the negative regulatory element of the human immunodeficiency virus long terminal repeat.

NLM AIDSLINE A novel T-cell protein which recognizes a palindromic sequence in the negative regulatory element of the human immunodeficiency virus long terminal repeat. Orchard K; Perkins N; Chapman C; Harris J; Emery V; Goodwin G; Latchman
September 30, 1990

J Virol. 1990 Jul;64(7):3234-9. Unique Identifier : AIDSLINE Two major protein-binding sites within the negative regulatory element of the human immunodeficiency virus type 1 long terminal repeat have been identified. One (site B) contained a palindromic sequence with homology to steroid/thyroid hormone response elements but was distinct from previously described binding sites of this class. A novel T-cell protein recognized the palindromic sequence within site B and also bound estrogen- or thyroid hormone-response elements with lower affinity. A 7-base-pair mutation in the site B palindrome, which destroyed protein binding, resulted in increased expression from the human immunodeficiency virus type 1 long terminal repeat in T cells. Base Sequence Cell Line DNA Mutational Analysis DNA-Binding Proteins/PHYSIOLOGY Gene Expression Regulation, Viral Human HIV-1/GENETICS In Vitro Methylation Molecular Sequence Data Nuclear Proteins/PHYSIOLOGY Regulatory Sequences, Nucleic Acid Repetitive Sequences, Nucleic Acid Repressor Proteins/PHYSIOLOGY Support, Non-U.S. Gov't T-Lymphocytes/*MICROBIOLOGY JOURNAL ARTICLE

Most Read: Latest Added Related Topics White House LGBT Conference on HIV/AIDS UNITED STATES: White House in Atlanta: LGBT AIDS Conference No more single-theme conferences: global HIV prevention conference planned FHI 360 Senior Scientist Lut Van Damme Receives International Microbicide Conference Lifetime Achievement Award Photographs from A Day with HIV Now Online Equatorial Guinea Ministry of Health and Social Welfare and UNICEF Refute Erroneous AIDS Prevalence Figures Bulgaria urges Libya to investigate AIDS nurses case Engineers enter fight against AIDS in Africa Gilead’s Complera® Non-Inferior to Atripla® Among Treatment-Naive HIV Patients UN chief Ban calls world leaders to end Aids by 2020 People with HIV pay more for life insurance – if they can get it (South Africa)Uganda: Gov't Urged to Levy a Tax On Alcohol to Fund HIV No time to lose in the search for an HIV vaccine India Widens Price Control Over Medicines Health group didn't disclose HIV tests, apologizes As Hepatitis C Spreads, Scotland Steps In Russia has 'no anti-AIDS strategy': official Uganda: Over 600 Circumcised in Masaka 1 new hepatitis case in Okla. public health scare NEW JERSEY: Drug Company Donates Thousands to HIV/AIDS Orgs PENNSYLVANIA: Scientists Weaken HIV Infection in Immune Cells Using Synthetic Agents How long does it take for HIV to show in the blood?Study Results from Eunice Kennedy Shriver National Institute of Child Health and Human Development Provide New Insights into HIV/AIDS Monetising Human Waste and 101 (Slightly) Crazy Other Ideas Inovio Pharmaceuticals Recognized With "Best Therapeutic Vaccine" and "Best Early Stage Biotech" Awards at World Vaccine Congress 2013 Data on SEEK's Novel Immunotherapy for HIV Published in Virology Journal Inhibikase Therapeutics to present at 5th International Congress on Polyomaviruses and Human Diseases - May 11, 2013 Grand Hotel Bristol, Stresa, Italy Anglo American Believes Long-term Thinking is Critical to Sustainable Development More than 60 dental patients test positive for viruses BELGIUM: Long-Term Suppression of Viral Load and Sustained CD4 Cell Increase Reduce Risk of Cervical HPV Infection for HIV-Positive Women
Information in this article was accurate in September 30, 1990. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.